Oncobiologics (ONS) Stock Rating Upgraded by ValuEngine

Oncobiologics (NASDAQ:ONS) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.

Separately, Barclays downgraded Oncobiologics from an “overweight” rating to an “equal weight” rating in a report on Monday, January 29th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $9.00.

Shares of Oncobiologics (ONS) remained flat at $$1.14 on Friday. 35,955 shares of the company were exchanged, compared to its average volume of 64,063. Oncobiologics has a fifty-two week low of $0.78 and a fifty-two week high of $3.77. The company has a quick ratio of 0.14, a current ratio of 0.14 and a debt-to-equity ratio of -0.40. The stock has a market capitalization of $28.42 and a price-to-earnings ratio of -0.67.

In other news, CFO Lawrence A. Kenyon sold 26,165 shares of the business’s stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $1.13, for a total transaction of $29,566.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Pankaj Mohan sold 114,677 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $1.17, for a total value of $134,172.09. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 284,508 shares of company stock valued at $328,317. Corporate insiders own 33.50% of the company’s stock.

An institutional investor recently raised its position in Oncobiologics stock. Sabby Management LLC grew its position in shares of Oncobiologics Inc (NASDAQ:ONS) by 5.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,365,763 shares of the company’s stock after acquiring an additional 127,293 shares during the quarter. Sabby Management LLC owned about 9.59% of Oncobiologics worth $2,371,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 17.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/04/oncobiologics-ons-stock-rating-upgraded-by-valuengine.html.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply